Dyslipidaemia is one of the well established modifiable cardiovascular disease (CVD) risk factors. Elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and to a lesser extent triglycerides are associated with an increased risk of atherosclerotic CVD and its clinical end points, Coronary Heart Disease, Cerebrovascular Disease and Peripheral Arterial Disease. In contrary, Elevated levels of high-density lipoprotein cholesterol (HDL-C) are inversely correlated with CVD risk. This is attributed to the anti-atherogenic role of HDL by removing cholesterol from the tissues to the liver "Reverse cholesterol transport" for further metabolism and excretion via bile. What are the possible mechanisms to augment the anti-atherogenic effect of HDL?